Skip to main content

Table 1 Primary Clinical and Echocardiographic Characteristics of the Participants

From: Assessment of left ventricular energy loss using vector flow mapping in patients with stages 1–3 chronic kidney disease

Parameters

CKD Patients (stage 1–3)

Control

(n = 41)

All

(n = 48)

N-HTN

(n = 10)

W-HTN

(n = 18)

P-HTN

(n = 20)

Age (years)

50.81 ± 12.41

48.10 ± 14.39

50.94 ± 13.07

52.05 ± 11.16

44.49 ± 11.53

Male (all)

28(48)

5 (10)

12 (18)

11 (20)

23 (41)

BMI (kg/m2)

25.57 ± 3.95*

24.67 ± 2.30

25.84 ± 4.04

26.27 ± 4.36

23.33 ± 2.92

HR (beats/min)

75.85 ± 11.03

77.50 ± 12.14

77.61 ± 9.91

73.45 ± 11.52

71.49 ± 9.52

SBP (mmHg)

138.19 ± 19.80*

125.40 ± 7.50

125.67 ± 2.18

155.85 ± 15.72& #

118.12 ± 11.03

DBP (mmHg)

83.96 ± 12.11*

79.30 ± 11.92

77.39 ± 6.16

92.20 ± 11.74& #

75.68 ± 11.50

BG (mmol/L)

5.01 ± 1.01

4.67 ± 0.52

4.87 ± 0.87

5.31 ± 1.23

4.78 ± 0.48

TC (mmol/L)

5.13 ± 1.42

5.55 ± 1.22

4.71 ± 1.65

5.31 ± 1.23

4.75 ± 0.70

TG (mmol/L)

1.94 ± 1.10*

1.75 ± 0.90

1.95 ± 1.28

2.03 ± 1.04

1.22 ± 0.38

HDL (mmol/L)

1.19 ± 0.36*

1.26 ± 0.47

1.07 ± 0.29

1.18 ± 0.30

1.48 ± 0.32

LDL (mmol/L)

3.10 ± 0.83

3.46 ± 0.90

2.87 ± 0.64

3.12 ± 0.91

2.97 ± 0.55

SCR (μmol/L)

267.02 ± 182.95*

201.42 ± 111.90

299.52 ± 245.93

270.57 ± 139.53

65.31 ± 10.88

CCR (ml/min)

41.20 ± 24.07*

44.76 ± 19.81

40.81 ± 24.15

39.78 ± 26.76

123.72 ± 27.99

ALB (g/l)

34.09 ± 4.79*

31.24 ± 6.03

35.03 ± 3.72

34.66 ± 4.66

45.18 ± 2.78

HB (g/l)

128.08 ± 17.15*

128.20 ± 18.93

127.72 ± 14.36

128.35 ± 19.30

140.22 ± 15.01

LVEDd (mm)

48.32 ± 5.30

47.20 ± 4.24

47.44 ± 4.71

49.68 ± 6.16

46.85 ± 3.79

IVS (mm)

10.60 ± 2.20

9.00 ± 1.83

10.67 ± 2.30

11.35 ± 1.93

8.26 ± 1.00

LVPW (mm)

9.33 ± 1.85*

8.20 ± 0.92

8.78 ± 1.31

10.40 ± 2.09& #

8.05 ± 0.90

LVEDV (ml)

111.10 ± 30.75

103.50 ± 20.68

106.39 ± 25.27

119.15 ± 38.02

103.07 ± 18.83

LVEF (%)

66.12 ± 6.16

66.09 ± 5.01

66.27 ± 4.95

66.05 ± 4.78

66.73 ± 4.34

LVMI (g/m2)

92.02 ± 5.46*

74.00 ± 15.40

82.28 ± 24.20

109.80 ± 43.37& #

72.05 ± 11.84

E (cm/s)

70.27 ± 17.04

63.40 ± 7.73

63.73 ± 15.99

79.60 ± 17.44& #

69.57 ± 12.24

A (cm/s)

77.47 ± 15.78*

69.90 ± 15.00

75.52 ± 17.76

83.02 ± 12.68

56.74 ± 15.19

E/e’

10.38 ± 3.33*

8.51 ± 1.32

10.34 ± 3.57

11.76 ± 3.04

6.07 ± 1.81

  1. Date given as mean ± Standard Deviation or number (total)
  2. ALB Albumin, A Mitral late filling wave peak velocity, BG Blood glucose, BMI Body mass index, CCR Creatinine clearance rate, CKD Chronic kidney disease, DBP Diastolic blood pressure, E Mitral early filling wave peak velocity, e’ Early mitral annular peak velocity on septal side, HDL High-density lipoprotein, HB Hemoglobin, HR Heart rate, LDL Low-density lipoprotein, LVEDd Left ventricular end-diastolic diameter, LVEDV Left ventricular end-diastolic volume, LVEF Left ventricular ejection fraction, LVMI Left ventricular mass index, LVPW Left ventricular posterior wall, IVS Interventricular septal thickness, N-HTN CKD patients (stage1–3) who had no hypertension, P-HTN CKD patients (stage1–3) who had poorly controlled hypertension, SBP Systolic blood pressure, SCR Serum creatinine, TC Total cholesterol, TG Triglycerides, W-HTN CKD patients (stage1–3) who had well-controlled hypertension
  3. *P < 0.05 vs. control; &P < 0.05 vs. N-HTN; #P < 0.05 vs. W-HTN)